Scotland · NHS Scotland MSAN
H2-antagonists (cimetidine, famotidine and nizatidine)
MSAN(2020)47 · Level 2 · issued 01 Jun 2020
What the notice states
The supply position for each affected product, as recorded in the notice — read the full signed PDF above for the clinical advice and actions.
| Product | Position | Resupply |
|---|---|---|
| Famotidine 20mg tablets: Teva are out of stock with resupply date to be confirmed; Tillomed have | Out of stock | — |
| limited stock with resupply date to be confirmed; | Resupply date to be confirmed | — |
| with resupply date to be confirmed; | Resupply date to be confirmed | — |
| Cimetidine 200mg tablets: Ennogen are back in stock; Medreich are out of stock with resupply | Out of stock | — |
| date to be confirmed; | Resupply date to be confirmed | — |
| Cimetidine 400mg tablets: Ennogen are out of stock until June 2021; Medreich are out of stock | Out of stock | June 2021 |
| with resupply date to be confirmed; | Resupply date to be confirmed | — |
| Cimetidine 800mg tablets: Ennogen are back in stock; Medreich are out of stock with resupply | Out of stock | — |
| date to be confirmed; | Resupply date to be confirmed | — |
| Nizatidine 150mg and 300mg tablets: Mylan are out of stock until the end of 2020; Medreich are out | Out of stock | the end of 2020 |
| of stock with resupply date to be confirmed. | Resupply date to be confirmed | — |
From the NHS Scotland notice PDF (linked above); dates and “valid until” text are as stated, fuzzy wording kept as written. Scotland is covered separately from England — see methodology. Not an official NHS service, and not clinical advice — follow the guidance issued to your pharmacy.